Chronic lymphocytic leukemia (CLL) is usually a slow-growing blood cancer. Most people with CLL don’t notice any problems in the early stages of the disease. “In fact, we can do what we call ...

Acute lymphoblastic leukemia (ALL ... to differentiate it from the very different disease of chronic lymphocytic leukemia, which has a potential time course of many years. It is interchangeably ...

TBI remained significantly associated with reduced adjusted risks of grade 3 to 4 aGVHD and moderate-severe cGVHD.

In Chronic Lymphocytic Leukemia (CLL), the bone marrow makes too many abnormal white blood cells, or lymphocytes. These cells never become healthy, infection-fighting cells. They interfere with the ...

People with chronic lymphocytic leukemia (CLL) may have a higher risk of developing skin cancers, such as melanoma, than those without CLL. They may also have less positive outlooks if they ...

Cardiovascular management strategies are essential to individuals with chronic lymphocytic leukemia (CLL) or multiple myeloma (MM) undergoing active treatment, due to the high rate of atrial ...

Highlights in acute lymphoblastic leukemia (ALL), presented at the American Society of Hematology (ASH) 2024 Annual Meeting and Exposition, include studies on pediatric and adult disease ...

The following is a summary of “Critically ill adult patients with acute leukemia: a systematic review and meta-analysis,” published in the January 2025 issue of Critical Care by Chean et al. Researche ...

Chronic Lymphocytic Inflammation with Pontine Perivascular ... For instance, one report described a young male patient who exhibited acute symptoms and showed significant improvement following ...

A research team made a pivotal discovery in the field of cancer immunotherapy. The team identified a specific population of immune cells that play a critical role in successful treatment of relapsed ...

New data suggest venetoclax may offset the negative prognostic impact of short telomeres in patients with chronic lymphocytic ...

The China-based drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is ...